Chemistry:Zosurabalpin

From HandWiki
Revision as of 08:36, 8 February 2024 by JMinHep (talk | contribs) (over-write)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Investigational antibiotic
Zosurabalpin
Zosurabalpin.svg
Clinical data
Other namesN2.2.2.1,3-anhydro(N2-[(2-([2-(aminomethyl)-4'-carboxy[1,1'-biphenyl]-3-yl]sulfanyl)pyridin-3-yl)methyl]-L-ornithyl-L-lysyl-N-methyl-L-tryptophan
Identifiers
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC43H50N8O5S
Molar mass790.98 g·mol−1
3D model (JSmol)

Zosurabalpin (RG6006, Abx-MCP, Ro7223280) is an experimental antibiotic developed in a collaboration between the pharmaceutical company Roche and scientists from Harvard University, for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB). It targets a lipopolysaccharide transporter.[1] It works by recognizing a composite binding site made up of both the Lpt transporter and its LPS substrate.[2] The chemical family to which it belongs was first disclosed in 2019, but the particular structure of RG6006 remained confidential until publication of the testing results in 2023.[3][4][5]

See also

References

  1. "A novel antibiotic class targeting the lipopolysaccharide transporter". Nature 625 (7995): 566–571. January 2024. doi:10.1038/s41586-023-06873-0. PMID 38172634. 
  2. "A new antibiotic traps lipopolysaccharide in its intermembrane transporter". Nature 625 (7995): 572–577. January 2024. doi:10.1038/s41586-023-06799-7. PMID 38172635. 
  3. Bleicher K, Cheang D, Di Giorgio P, Hu T, Jenny C, Mattei P, Schmitz P, Stoll T, "Peptide macrocycles against acinetobacter baumannii.", US patent 20190321440A1, issued 21 November 2023
  4. "2109. In vitro and in vivo Killing Kinetics of Zosurabalpin (RG6006) Against Acinetobacter baumannii.". Open Forum Infectious Diseases. 10. Oxford University Press. December 2023. doi:10.1093/ofid/ofad500.1733. 
  5. "Evaluating the innovative potential of the global antibacterial pipeline". Clinical Microbiology and Infection. October 2023. doi:10.1016/j.cmi.2023.09.024. PMID 37805036.